These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36154787)
1. Radiotherapy for Pancreatic Adenocarcinoma: Recent Developments and Advances on the Horizon. Salamekh S; Gottumukkala S; Park C; Lin MH; Sanford NN Hematol Oncol Clin North Am; 2022 Oct; 36(5):995-1009. PubMed ID: 36154787 [TBL] [Abstract][Full Text] [Related]
2. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234 [TBL] [Abstract][Full Text] [Related]
3. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Holyoake DL; Ward E; Grose D; McIntosh D; Sebag-Montefiore D; Radhakrishna G; Patel N; Silva M; Mukherjee S; Strauss VY; Odondi L; Fokas E; Melcher A; Hawkins MA BMC Cancer; 2016 Sep; 16(1):728. PubMed ID: 27619800 [TBL] [Abstract][Full Text] [Related]
8. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605 [TBL] [Abstract][Full Text] [Related]
9. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy? Huguet F; Cerbai C; Ta MH; Sarrade T; Evin C; Aziez S; Rivin Del Campo E; Durand B; Loi M Cancer Radiother; 2022 Oct; 26(6-7):858-864. PubMed ID: 35987811 [TBL] [Abstract][Full Text] [Related]
12. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389 [TBL] [Abstract][Full Text] [Related]
14. Radiation therapy in borderline resectable pancreatic cancer: A review. Turner KM; Delman AM; Kharofa JR; Smith MT; Choe KA; Olowokure O; Wilson GC; Patel SH; Sohal D; Ahmad SA Surgery; 2022 Jul; 172(1):284-290. PubMed ID: 35034793 [TBL] [Abstract][Full Text] [Related]
15. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479 [TBL] [Abstract][Full Text] [Related]
16. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971 [TBL] [Abstract][Full Text] [Related]
17. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642 [TBL] [Abstract][Full Text] [Related]
18. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644 [TBL] [Abstract][Full Text] [Related]
19. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings. Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059 [TBL] [Abstract][Full Text] [Related]
20. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]